Press Releases

KB109 demonstrated favorable safety and tolerability profile Kaleido intends to file an Investigational New Drug (IND) application, with the goal of advancing KB109 directly into a pivotal registration program Company to host conference call today at 8:30am ET LEXINGTON, Mass., March 24, 2021
Read More
Displaying 1 - 10 of 12
Print Page
Email Alerts
Investor Contact